Latest news with #Non-Hodgkin'sLymphoma
Business Upturn
11 hours ago
- Business
- Business Upturn
Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
NIJMEGEN, The Netherlands: Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation and expansion BYON4228.002 clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of novel SIRPα-directed monoclonal antibody (mAb) BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. Advertisement This press release features multimedia. View the full release here: Louis Denis, MD, Chief Medical Officer, Byondis BYON4228 is a potential best-in-class novel mAb that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. By targeting SIRPα and not CD47, BYON4228 offers selective targeting of myeloid cells and avoids disruption of other biologically meaningful CD47-dependent interactions. In preclinical studies, BYON4228 was found to potentiate the tumor killing capacity of tumor-targeting mAbs tested without the toxicity associated with CD47 agents. 'Building on strong preclinical data, we believe that there is broad potential for BYON4228 alone and in combination with tumor-targeting mAbs, checkpoint inhibitors and antibody drug conjugates and other modalities across hematological and solid tumors,' said Louis Denis, MD, Chief Medical Officer, Byondis. 'We look forward to evaluating the results of this trial to support the clinical development of BYON4228 alone and in combination with other agents and to bring a new therapeutic option to patients with high unmet medical need.' Part 1 of the BYON4228.002 trial will evaluate the safety of BYON4228 alone and in combination to determine the maximum tolerated dose (MTD), or optimal biological dose (OBD) if the MTD is not reached, and recommended combination dose regimen(s) for expansion (RDE(s)). The second part of the trial will evaluate the objective tumor response rate (ORR). The secondary objectives of this trial are safety, pharmacokinetics, immunogenicity and preliminary efficacy. The trial will be conducted at multiple sites across Europe, including the United Kingdom, Belgium and Spain. About BYON4228 BYON4228 is a novel monoclonal antibody (mAb) from Byondis' next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors' ability to escape from recognition and destruction by the immune system. BYON4228 is currently being studied in two Phase 1 Clinical Trials evaluating BYON4228 alone and in combination with Rituximab in patients with Relapsed/Refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL) (NCT05737628) and BYON4228 alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors (NCT06932952). About Byondis Driven to improve patients' lives, Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics. Byondis' broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis' expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis' expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house. The company's headquarters and state-of-the-art R&D and GMP manufacturing facilities are based in Nijmegen, the Netherlands. For more information visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
5 days ago
- Business
- Yahoo
Intermountain Health first in nation to expand stem cell collection for CAR-T Cell Therapy bringing innovative cancer procedure to Southern Utah
ST. GEORGE, Utah (ABC4 Utah) – Intermountain Health is now offering a national first-of-its kind expansion of CAR-T Cell Therapy, bringing cutting-edge cancer care closer to patients in Southern Utah and Nevada. Intermountain's new CAR-T Cell satellite clinic in St. George marks a significant milestone to improve access to FDA approved CAR T-cell therapies at a regional clinic – and is the first time in the United States that CAR T-Cell collections are now available at a remote site away from a primary treatment center. Before expanding the CAR T-Cell therapy program, patients in southwest Utah, Nevada and beyond, had to travel hundreds of miles to Intermountain LDS Hospital in Salt Lake City for collection, transplant, and follow-up care. This innovative expansion of stem cell collection and CAR T-cell collection procedures at the Intermountain Health St. George Cancer Center provides advanced cancer treatment options closer to home for patients in the region. 'Expanding CAR-T Cell Therapy to Intermountain St. George Regional Hospital is a testament to our commitment to providing accessible, state-of-the-art cancer treatment,' said Brad Hunter, MD, medical oncologist and director of the CAR T-cell program at Intermountain LDS Hospital. 'This clinic will significantly enhance the quality of care for patients in Southern Utah and beyond our state boarders, offering them hope and healing without the need to travel long distances.' CAR-T Cell Therapy is a form of immunotherapy that harnesses the power of a patient's own immune system to fight cancer by genetically reprogramming T-cells to target and destroy cancer cells. 'This therapy has shown remarkable success in treating certain types of leukemia and non-Hodgkin lymphoma and we're grateful for the chance to make it more accessible,' said Dr. Hunter. This process is customized to each individual oncology patient and involves collecting the patient's immune cells or T cells, which are then sent to a different location and re-engineered. About two to three weeks later the patient will travel to Intermountain LDS Hospital for the re-programmed cells to be transplanted back to the patient. The new cells then target and kill the cancer cells by binding to the specific proteins or antigens on the cancer cells. The patient is observed to confirm the treatment is working and then sent home, with follow up appoints close to home. Jacqueline, 68, from Las Vegas, Nevada, received CAR-T therapy for her Non-Hodgkin's Lymphoma last year at Intermountain LDS Hospital and says it saved her life. 'It was really miraculous,' said Jacqueline. 'I could see the back of my throat and see the lymph nodes, so swelled up and then within two weeks of the treatment, suddenly, they were just gone. They even scanned me and everything was gone.' Jacqueline and her husband had to travel to Salt Lake numerous times and stay for a month, they say the new Intermountain Health St. George CAR-T Cell satellite clinic will save some miles and will be nice for future cancer patients to have treatment, 'just down the street.' CAR T-Cell therapy is currently FDA approved for patients who have a variety of hematologic cancers, including acute lymphoblastic leukemia (ALL), B-cell lymphomas, and multiple myeloma. For more information about the Intermountain Health CAR-T Cell Therapy program and services, go to Intermountain Health. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Sposored by Intermountain Health. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 days ago
- Business
- Yahoo
Khloe Kardashian's Good American Set for Trial With Cancer-Stricken Ex-Employee Over Firing
Khloé Kardashian's fashion company, Good American, was unable to reach a settlement with the cancer-stricken ex-employee suing for wrongful termination and are set for trial, In Touch can exclusively report. According to court documents obtained by In Touch, a hearing was held on Tuesday, April 29, as part of the lawsuit against Good American brought by a woman named Brooke. Khloé, 40, launched the company with her business partner, Emma Grede, in 2016, At the hearing, it was revealed the parties recently attended a hearing in an attempt to hash out a deal to avoid going to trial. The judge noted the parties did not settle the case. The jury trial is scheduled for August 4 in Los Angeles Superior Court. In the bombshell lawsuit, Brooke said she was hired in 2019 as a Marketing Intern. She was promoted to Marketing Coordinator in June 2021. Brooke said she was provided with glowing performance reviews praising her as an 'asset to the team' and 'great on Emma and Khloé projects.' In 2022, Brooke said she was promoted to Social Media Manager and given a raise. She said she was given another raise in early 2023. On June 20, 2023, Brooke, who had previously been treated for cancer (Non-Hodgkin's Lymphoma) submitted a doctor's note to her bosses from UCLA Department of Medicine. The note said that Brooke was under a doctor's professional care and that she was requested as an accommodation a 'temporary excuse from work.' The note said Brooke was "immune compromised' and had recently been discharged from the hospital. Further, it said Brooke needed to complete a course of treatment and that she needed to return to work remotely. Brooke said she submitted another note in July 2023, stating she was under 'medical care' and that she was unable to work in person and needed more time to work remotely. In the suit, Brooke accused the defendants of undertaking a pressure campaign, in which defendants made negative comments to her about her need for accommodation. She claimed she was told her need for accommodation was undermining the organization and that her bosses suggested she take a medical leave of absence instead of working remotely. 'Despite defendants' pressure campaign, plaintiff continued to perform her job remotely, in an effective and competent manner,' the suit read. She said she later saw a job listing for her role. Brooke submitted another request for accommodation in September 2023 that said she needed to continue working at home. The doctor note said Brooke 'is extremely immunocompromised due to her underlying medical condition.' The following month, Brooke claimed Good American terminated her due to a company 'layoff.' Brooke disputed it was a 'layoff' and alleged the company had continued to hire and fill roles. Brooke claimed she was terminated due to her medical condition and disability. The suit demanded damages from Good American and Emma for wrongful termination, cancer discrimination and intentional infliction of emotional distress. Khloé was not a named defendant in the lawsuit. Good American and Emma denied all allegations of wrongdoing. '[Brooke] is barred from claiming any injuries or damages because such injuries and damages are the sole, direct and proximate result of [Brooke's] conduct,' the response read. Further, their lawyer argued, 'To the extent [Brooke] suffered any symptoms of mental or emotional distress or injury, it was the result of pre-existing psychological disorders or alternative concurrent causes, and not the result of any act or omission of Defendants.' Also, they said, 'Plaintiff's claims for failure to accommodate are barred because Plaintiff never gave notice of the need for an accommodation.' The lawyer also claimed Brooke had preexisting issues due to her cancer. '[Brooke] had preexisting mental distress due to cancer and other alternative causes that existed before she was terminated. Any alleged emotional distress was not due to the alleged actions of Defendants,' they argued. Khloé's company also denied cancer or Brooke's need for accommodations were the reason for her termination. They demanded the entire suit be thrown out.
Yahoo
6 days ago
- Business
- Yahoo
Khloe Kardashian's Company Demands Cancer-Stricken Ex-Employee Submit to Mental Exam
Khloé Kardashian's fashion company, Good American, demanded the cancer-stricken ex-employee suing for alleged discrimination submit to a mental examination before trial, In Touch can exclusively report. On May 23, lawyers for Good American and Khloé's business partner, Emma Grede, filed court docs, obtained by In Touch, which asked the court to sign off on the former employee, Brooke, being examined by a medical professional. Khloé, 40, and Emma, 42, launched the company in 2016. In her suit, Brooke claimed she was hired in 2019 and received positive reviews throughout. She said issues started after she asked for accommodations due to her health. Good American and Emma denied all allegations of wrongdoing. In her suit, Brooke claimed the defendants caused her to suffer mental and emotional injuries, including anxiety, stress, self-doubt, worry, frustration, depression and embarrassment. The lawyer for the defendants said Brooke revealed that she had received therapy for her alleged injuries. The attorney said they tried to get Brooke to agree to an independent medical exam by a doctor they selected. Brooke allegedly refused to engage with the request. The lawyer argued, '[Brooke's] allegations of emotional and mental distress make it clear that her emotional and mental states are 'in controversy', and as [Brooke] will surely seek to recover such damages should she prevail on his claims. Therefore, good cause exists to compel the mental examination of [Brooke].' He added, 'The requested examination will allow Defendants to adequately defend themselves against [Brooke's] claims of emotional and mental distress as alleged in [Brooke's] Complaint, and will also allow Defendants to test the veracity of [Brooke's] mental and emotional distress claims.' The court has yet to rule on the matter. As In Touch previously reported, in her lawsuit, Brooke claimed she was hired by Good American in 2019 as a Marketing Intern. She said she received various promotions and rave reviews over the years. In 2023, Brooke, who had previously been treated for cancer (Non-Hodgkin's Lymphoma), submitted a doctor's note to her bosses. The note from UCLA Department of Medicine said Brooke was immunocompromised and had recently been discharged from the hospital. The letter said Brooke should work remotely until she had finished another round of treatment. Brooke said the defendants were not happy and pressured her to take a medical leave instead of working remotely. She said she was told her accommodations were undermining the organization. Later, Brooke said she saw a job listing for her role. The next month, she said Good American laid her off due to a company-wide 'layoff.' Brooke does not believe it was a 'layoff' but rather Good American getting rid of her due to her disability. She sued seeking unspecified damages for wrongful termination, cancer discrimination and intentional infliction of emotional distress. Good American and Emma denied all allegations of wrongdoing in the case. An attorney for the defendants argued, 'To the extent [Brooke] suffered any symptoms of mental or emotional distress or injury, it was the result of pre-existing psychological disorders or alternative concurrent causes, and not the result of any act or omission of Defendants.' In addition, the lawyer alleged, '[Brooke] is barred from claiming any injuries or damages because such injuries and damages are the sole, direct and proximate result of [Brooke's] conduct.' Good American and Emma claimed Brooke had preexisting conditions due to her cancer. '[Brooke] had preexisting mental distress due to cancer and other alternative causes that existed before she was terminated. Any alleged emotional distress was not due to the alleged actions of Defendants,' the response argued. Good American claimed all decisions made were business-related and not discriminatory.
New York Post
22-05-2025
- Sport
- New York Post
Red Sox's Liam Hendriks condemns fans over death threats made against him and his wife after loss to Mets
Red Sox pitcher Liam Hendriks condemned the social media users who made threats against his and his wife's lives following Boston's 5-1 home loss to the Mets on Wednesday night. In a message posted Thursday on his Instagram Story, Hendriks — who relieved Garrett Crochet in the sixth and gave up three hits in the seventh — told commenters spewing such vitriol at his family they 'need help' and need to 'reevaluate [their] life's purpose.' 'Threats against my life and my wife's life are horrible and cruel. You need help,' the 36-year-old Hendriks began, referencing his wife, Kristi. Advertisement 5 Liam Hendriks hit back at online trolls making threats against his life and the life of his wife, Kristi. Getty Images 5 The Boston Red Sox pitcher posted a message on his Instagram Story calling out the vitriol he and his family endured. Instagram 'Leaving comments telling me to commit suicide and how you wish I died from cancer is disgusting and vile. Advertisement 'Maybe you should take a step back and reevaluate your life's purpose before hiding behind a screen attacking players and their families.' The three-time MLB All-Star has been to hell and back in his return to the mound. 5 Liam Hendriks on the mound for the Red Sox on May 21, 2025. Eric Canha-Imagn Images Hendriks revealed in January 2023 he had been diagnosed with Non-Hodgkin's Lymphoma and had started treatment. He was declared cancer-free that April. Advertisement He then underwent Tommy John Surgery in August 2023 while a member of the Chicago Red Sox. Hendriks made his debut for Boston on April 20, 2025 — his first major league game since June 2023. 5 Liam Hendriks made his Red Sox debut in April 2025. Eric Canha-Imagn Images The 2023 AL Comeback Player of the Year made it clear to trolls on Thursday there's no place for this reprehensible behavior. Advertisement 'I think I speak for all players who have had to deal with this in their career when I say: Enough is enough,' he concluded. 5 Liam Hendriks with wife Kristi in 2024. MLB Photos via Getty Images Hendriks, owner of a 5.56 ERA through 11 games, said Wednesday more reps will yield better results if only given an opportunity. 'I feel like I haven't been pitching enough and if you wanted me to be me, I got to pitch,' he said, according to NESN. 'I will rust before I wear out. At the end of the day, I've got to reward them by throwing me by getting guys out. And if I'm not doing that then I don't deserve to pitch.' Hendriks has pitched across six MLB teams in his career, including the Twins, Blue Jays, Royals and A's. He and Kristi have been married since 2013.
